Cabazitaxel (Cbz) versus topotecan in patients (pts) with small cell lung cancer (SCLC) that has progressed during or after first-line treatment with platinum-based chemotherapy: A randomized phase II study.
Tracey L. Evans
No relevant relationships to disclose
Joo-Hang Kim
Research Funding - Bristol-Myers Squibb; Lilly; Roche
Frances A. Shepherd
Consultant or Advisory Role - AstraZeneca; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck; Recombio; Roche
Stock Ownership - Lilly; Pfizer
Honoraria - GlaxoSmithKline; Lilly; Roche
Expert Testimony - AstraZeneca
Konstantinos N. Syrigos
No relevant relationships to disclose
Katalin Udud
No relevant relationships to disclose
Viacheslav Chubenko
No relevant relationships to disclose
Dariusz Kowalski
No relevant relationships to disclose
James R. Rigas
No relevant relationships to disclose
Gregory Lo
No relevant relationships to disclose
Jaafar Bennouna
Consultant or Advisory Role - Boehringer Ingelheim; Roche
Honoraria - Boehringer Ingelheim; Roche
Mustapha Chadjaa
Employment or Leadership Position - Sanofi
Martin Wolf
No relevant relationships to disclose